Thermo Fisher Scientific (NYSE:TMO) has revealed the launch of a new syndicated clinical registry by CorEvitas focused on generalized pustular psoriasis (GPP). This registry, now open for enrollment, marks CorEvitas’ 10th syndicated disease registry, aiming to address the critical need for real-world evidence concerning clinical outcomes and patient-reported outcomes among GPP patients.
It’s worth noting that Thermo Fisher’s acquisition of CorEvitas in August 2021 has significantly expanded its Laboratory Products and Biopharma Services segment by incorporating highly complementary real-world evidence solutions, aimed at enhancing decision-making processes and streamlining drug development efforts. This recent initiative provides a notable boost to the PPD clinical research business within this segment.
In-Depth Insight
The rare GPP condition affects approximately one in every 10,000 individuals in the United States, with studies indicating a higher prevalence among women than men. It manifests as a sudden eruption of rash and sterile pustules across the body, often accompanied by systemic inflammation, recurring either annually or more frequently. These flares can lead to severe complications, potentially becoming life-threatening if untreated.
Significant strides have been made by researchers and healthcare professionals in managing GPP therapy and controlling comorbidities associated with the disease. The newly launched CorEvitas clinical registry will facilitate the prospective collection of detailed patient-level data, enabling a comprehensive understanding of the disease’s natural progression, treatment trends, and the prevalence of comorbidities among affected individuals.
During registry visits, granular and longitudinal outcome measures will be gathered, encompassing clinician-reported GPP outcomes, laboratory data, treatment histories, as well as patient-reported outcomes assessing symptom impact and overall quality of life. Additionally, the registry will compile drug safety data, including reports of serious adverse events and other notable adverse events.
Industry Outlook
According to research projections, the global market for real-world evidence solutions is anticipated to reach $2 billion by 2024, with an expected compound annual growth rate (CAGR) of 16.5% during the period spanning 2024 to 2029.
Advancements in the Laboratory Products and Biopharma Services Division
In recent developments, Thermo Fisher’s PPD business expanded its service portfolio at its good manufacturing practices (GMP) laboratory in Middleton, WI, by introducing mycoplasma and additional biosafety testing capabilities. This expansion aims to ensure that biopharmaceutical products remain free from contaminants, thus enhancing the safety of medicines delivered to patients.
Moreover, in January 2024, the company received GMP approval from the Italian Medicines Agency for its RNA-based product manufacturing facility in Monza, Italy. This approval, alongside associated certifications, facilitates broader access to novel therapies for patients grappling with challenging medical conditions, marking a significant milestone within the Thermo Fisher Scientific network and for Italy as a whole.
Price Performance
Over the past six months, TMO shares have exhibited a 17% increase, outpacing the industry’s growth of 14.9%.
Featured Image: Freepik